$ARDX Scotiabank initiated coverage of Ardelyx (ARDX) with an Outperform rating and $15 price target. The firm sees “an attractive entry point” as it believes concerns that sales for Xphozah for hyperphosphatemia cannot be significant without Medicare Part D coverage are

‼️YOUR 2025 NATIONAL CHAMPIONS‼️ #hobarthockey #d3hky

$SOFI 🚨BREAKING NEWS 🚨 10 Analyst have updated their price targets William Blair $25 Needham $20 Mizuho $20 JP Morgan $16 UBS $15.50 Bank Of A $13 Barclays $12 Goldman S $9.50 KBW

Insane its May 1st and no $NWBO news from #MHRA.

Anyone else think Tarrrifs are just the means to impose a consumption tax? May even get it for 50-75 cents on the dollar. Not a bad ROI.

Mizuho's Dan Dolev maintains his Outperform (buy) rating on $SOFI and increases his price target to $26 from $20. tipranks.com/news/the-fly/s…

$NWBO The 2025 CNS Annual Meeting: CNS Connects, is the premier neurosurgical conference focused on fostering meaningful connections in an increasingly complex and diverse field. Positioned at the intersection of innovation and tradition, this event celebrates the diversity of

apwriter Dr. Linda Liau speaks at 75th annual meeting of Congress of Neurological Surgeons (CNS) on 10/14/2025. Her talk will feature $NWBO #DCVax-L, Bench to Bedside: Evolution of Clinical Trials - DCVax-L for Primary and Recurrent GBM. CNS is a global organization comprised of 11,000+

Odds that $SOFI just signed a deal with Josh Allen just went up exponentially!

Want to give a shout out to amit for passing 100k followers!! I was introduced to amit back in the SOFI WEEKLY days. He has taken his opportunity and made into substantially more. #Respect

$SoFi Noto on the front page of Wharton magazine

This paper was published today 10/16/2025. It has some profound statements about $NWBO #DCVax-L dendritic cell vaccine technology platform including: “DC vaccines loaded with tumor lysates are a promising treatment strategy with potential therapeutic efficacy demonstrated in

Q3 was another record quarter for SoFi with $950 million in adjusted net revenue, up 38% y/y, 905,000 new members and product growth of 36%. We're delivering durable growth and strong returns fueled by the strength of our innovation and the power of our one-stop shop strategy.

$NWBO uclahealth.org/news/article/b… "DCVax-L potentially represents one of the first successful brain cancer vaccines and a milestone in the field of cancer immunotherapy."

$NWBO... COULD IT BE? 👀

Penn State has one more bowl win than OSU and Michigan this season.

$NWBO Great news here. This is proof of how legitimate #DCVax is becoming. All things are moving in our direction. Northwest Bio is the only named company in the article prnewswire.com/news-releases/…

$SOFI Tannor Manson LFGGGG!!! youtube.com/watch?v=bvLmxy…

When was alsg time $nwbo released quarterly earnings?

It doesn’t sound like $NWBO is expecting the MHRA to decline the approval of #DCVax. NWBio is making moves to add in-house dedicated leukapheresis capacity, expand Advent manufacturing capacity & add a seasoned Strategic Adviser: prnewswire.com/news-releases/…